Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab plus haplo-identical allogeneic activated NK cells for relapsed or refractory B-cell non-Hodgkin lymphoma
IRCT20230801058996N6Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab and allogeneic natural killer cells in B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoint: Adverse effects during or after combination therapy with allogeneic NK cells and rituximab. Started Jun 2024; status: completed.
02
Drugs
rituximaballogeneic natural killer cells
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on IRCT20230801058996N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230801058996N6.